Arresting Developments in Biased Signaling

The ability to design ‘biased’ drugs that selectively activate G protein-coupled receptor (GPCR) signaling pathways beneficial in treating a disease, while limiting their side effects, is of broad significance. Lee et al. move us a step closer to this important goal by identifying structural differe...

Full description

Saved in:
Bibliographic Details
Published in:Trends in pharmacological sciences (Regular ed.) 2020-06, Vol.41 (6), p.387-389
Main Authors: Yoo, Sungsoo M., Bhardwaj, Anshul, Benovic, Jeffrey L.
Format: Article
Language:English
Subjects:
Animals
arrestin
beta-Arrestin 1 - chemistry
beta-Arrestin 1 - metabolism
Biomimetic Materials - chemistry
cryo-EM
G protein-coupled receptor
Humans
Models, Molecular
Molecular Targeted Therapy
Receptors, Adrenergic, beta-1 - chemistry
Receptors, Adrenergic, beta-1 - metabolism
Receptors, G-Protein-Coupled - agonists
Receptors, G-Protein-Coupled - chemistry
Receptors, G-Protein-Coupled - metabolism
Signal Transduction - drug effects
Single-Domain Antibodies - chemistry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The ability to design ‘biased’ drugs that selectively activate G protein-coupled receptor (GPCR) signaling pathways beneficial in treating a disease, while limiting their side effects, is of broad significance. Lee et al. move us a step closer to this important goal by identifying structural differences in the β1-adrenoceptor in complex with β-arrestin 1 versus a G protein-mimicking nanobody.
ISSN:0165-6147
1873-3735
DOI:10.1016/j.tips.2020.04.003